Compare MNMD & THS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNMD | THS |
|---|---|---|
| Founded | 2019 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | N/A | N/A |
| Metric | MNMD | THS |
|---|---|---|
| Price | $13.44 | $23.71 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 7 |
| Target Price | ★ $30.33 | $24.67 |
| AVG Volume (30 Days) | ★ 2.0M | 671.8K |
| Earning Date | 11-06-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,336,000,000.00 |
| Revenue This Year | N/A | $1.43 |
| Revenue Next Year | N/A | $0.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.70 | $15.85 |
| 52 Week High | $14.43 | $40.77 |
| Indicator | MNMD | THS |
|---|---|---|
| Relative Strength Index (RSI) | 58.52 | 59.04 |
| Support Level | $12.70 | $23.46 |
| Resistance Level | $14.28 | $23.73 |
| Average True Range (ATR) | 0.70 | 0.18 |
| MACD | 0.10 | -0.14 |
| Stochastic Oscillator | 62.28 | 41.13 |
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
TreeHouse Foods is the largest pure-play private-label manufacturer in the US. Much larger in the past following the 2016 acquisition of Ralcorp, Conagra's former private-label business, the company has since divested several businesses to focus on high-growth categories. At present, the company produces and sells snacks (crackers, pretzels, cookies, and so on), beverages (such as nondairy creamer, coffee, tea, broth), and a select number of grocery products (pickles, refrigerated dough, hot cereal, cheese, and pudding). Its most important sales channel is through retail grocery stores that sell its products under their own brands, with co-manufacturing and food away from home as much smaller channels of distribution for its fare.